JCO Global Oncology最新文献

{"title":"Efficacy and Safety of Short Intravenous Hydration for Preventing Nephrotoxicity From High-Dose Cisplatin: A Randomized, Open-Label, Phase II Trial.","authors":"Apichart Jantarat, Lucksamon Thamlikitkul, Kullathorn Thephamongkhol, Jiraporn Setakornnukul, Pochamana Phisalprapa, Chayanis Kositamongkol, Thatsaphan Srithongkul, Suthinee Ithimakin","doi":"10.1200/GO-24-00515","DOIUrl":"https://doi.org/10.1200/GO-24-00515","url":null,"abstract":"<p><strong>Purpose: </strong>The use of short hydration (SH) to prevent cisplatin-induced nephrotoxicity lacks substantive prospective evaluation. The aim of this study was to evaluate the safety and efficacy of SH, including those with head and neck cancer (HNC) who are at higher risks of mucositis that causes diminished oral intake.</p><p><strong>Methods: </strong>This phase II randomized noncomparative trial included patients with cancer who were scheduled to receive high-dose cisplatin (≥60 mg/m²) in combination with another chemotherapy or concurrently with radiotherapy. Patients were randomly assigned to receive either the SH or conventional hydration (CH) protocol. The primary end point was the proportion of patients with increased serum creatinine (SCr) after undergoing SH. Secondary end points included the severity of SCr elevation, adverse events, cisplatin modification as a result of nephrotoxicity, duration of hospital stay, quality of life (QoL), and cost.</p><p><strong>Results: </strong>Among 100 enrolled patients, 64 and 36 patients underwent the SH and CH protocols, respectively. The median duration of chemotherapy infusion and intravenous hydration were 5.79 and 27.58 hours with SH and CH, respectively. A total of 32.8% and 33.3% of the SH and CH groups, respectively, experienced SCr elevation. Grade 2 SCr elevations were rarely observed in both groups (1.6% in SH, 2.8% in CH). Rate of cisplatin modification was similar between the two groups. Out of 82 patients with HNC, the rate of SCr elevation was comparable for both hydration protocols. The QoL scores were meaningfully higher in the SH group during the second cycle of cisplatin, although the overall direct medical costs were similar.</p><p><strong>Conclusion: </strong>The SH protocol is feasible and safe, with a remarkably reduced duration of administration. Thus, SH can be an alternative to CH in the prevention of cisplatin-related nephrotoxicity.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400515"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicentric Cross-Sectional Survey to Assess the Variation of Fractionation Strategies Used in the Management of Head and Neck Cancers in the Asian Region (INNOCENCE-ASIA).","authors":"Ajeet Kumar Gandhi, Supriya Chopra, Madhup Rastogi, Indranil Mallick, Misael C Cruz, Koichi Yasuda, Ying Ying Sum, Yasushi Nagata, Hong-Gyun Wu, Gregorius B Prajogi, Henry Kodrat, Mingwei Ma, Asif Nisar, Imjai Chitapanarux","doi":"10.1200/GO-24-00349","DOIUrl":"https://doi.org/10.1200/GO-24-00349","url":null,"abstract":"<p><strong>Purpose: </strong>Head and neck cancers (HNCs) are in general treated with conventional fractionation regimen of 1.8-2 Gy per fraction. Altered fractionation (ALFT) strategies such as hypofractionation radiotherapy (HYPO-RT), accelerated fractionation radiotherapy (AFRT), and hyperfractionation radiotherapy (HFRT) have not been practiced uniformly across centers in different parts of the world. Countries in Asia share common cancer demographics, and we designed this survey for Federation of Asian Radiation Oncology (FARO) member countries to understand the usage and challenges in the delivery of ALFT in HNCs.</p><p><strong>Materials and methods: </strong>A 21-point electronic survey (Federation of Asian Radiation Oncology Research Network [FERN]-S-005) was designed by the FERN and was circulated through the FARO research secretariat to the FARO council member countries and the responses were collected between August and November 2023.</p><p><strong>Results: </strong>Twelve of 14 member countries (85.7%) responded to the survey. Twenty-seven responses were received and 78% of the respondents belonged to government/teaching academic institute. 4/27 (14.8%) reported never using HYPO-RT for any of the clinical subsite of HNCs, while the majority (85.2%) used it for glottic cancers and 22% also used it for postoperative setting. Majority (77.7%) used a fractionation schedule with dose per fraction ranging between 2.2 and 2.5 Gy. 6/27 (22.2%) used AFRT for definitive setting and five of these also used concurrent chemoradiotherapy. 4/27 (14.8%) centers reported using HFRT. The most common reason (62.9%) for the limited usage of AFRT/HFRT was reported to be logistical, such as unavailability of machine slots, patient load, and so on.</p><p><strong>Conclusion: </strong>The result of the survey suggests that among the ALFT strategies for HNCs, HYPO-RT schedules have common interest and feasibility among the FARO member countries and also highlights the challenges in the delivery of AFRT/HFRT in the Asian region.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400349"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Pattern and Outcome of Locally Advanced Rectal Cancer in Resource-Constrained Countries: Experience at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.","authors":"Elias Amare Hailu, Edom Seife Woldetsadik, Biruk Legesse Tadesse, Abdi Dandena Dibaba, Girum Tessema Zingeta, Hidagewoin Frew Kelemu, Yonas Alemayehu Zewde, Ruth Shimeles Aytehgeza, Kebede H Begna","doi":"10.1200/GO.23.00407","DOIUrl":"https://doi.org/10.1200/GO.23.00407","url":null,"abstract":"<p><strong>Purpose: </strong>Management of locally advanced rectal cancer (LARC) includes neoadjuvant chemoradiotherapy (NACRT) followed by total mesorectal excision. Recently, total neoadjuvant treatment (TNT) has gained attention. In developing countries, patients with rectal cancer often present at advanced stages. This study assesses treatment patterns and outcomes in LARC at a largest referral center in Ethiopia.</p><p><strong>Materials and methods: </strong>A cross-sectional study was conducted on 100 patients with LARC treated at Tikur Anbessa Specialized Hospital from January 2020 to September 2022.</p><p><strong>Results: </strong>The median age at diagnosis was 45.5 years (range, 20-86), with 51% male. Of the patients, 81% had no previous oncologic treatment and 75.3% was discussed in a multidisciplinary tumor board. Up-front surgery was planned for 44.4% of patients, whereas 22.2% and 8.6% were assigned to TNT and NACRT, respectively. Among 81 treatment-naïve patients, 79 were triaged for surgery, but only 47 (59.5%) underwent surgery, achieving an 89.9% R0 resection rate. Of 36 up-front planned surgeries, 35 proceeded as planned, whereas only 12 of 43 (28%) planned after neoadjuvant treatment underwent surgery. Neoadjuvant chemotherapy (NACT) was given to 37% of patients, with 16.7% (5 of 30) undergoing subsequent surgery. Radiotherapy was given to 24.2% of participants, with 56.25% undergoing surgery. Short-course radiotherapy (SCRT) was given to two patients. Only 14.8% completed all planned treatments, with radiation waiting time (median, 10 months) being the main impediment.</p><p><strong>Conclusion: </strong>Timely administration of neoadjuvant treatment is not possible in most resource-limited settings. Because of better treatment completion, up-front surgery looks a more viable option than NACT in these situations. Extended waiting time for radiotherapy can be mitigated by opting for alternatives like SCRT in selected patients.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2300407"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral Mediastinal Lymphadenectomy Is Associated With Potential Survival Advantages in Patients With Stage I Non-Small Cell Lung Cancer Who Undergo Lung Resection.","authors":"Wei-Dong Wang, Gong-Ming Wang, Hong-Xu Sheng, Yu-Tong Hong, Dechang Zhao, Jian Hu, Lan-Jun Zhang","doi":"10.1200/GO.24.00219","DOIUrl":"https://doi.org/10.1200/GO.24.00219","url":null,"abstract":"<p><strong>Purpose: </strong>The optimal lymphadenectomy approach for solid-dominant stage I non-small cell lung cancer (NSCLC) is controversial. We compared postlobectomy survival outcomes to elucidate.</p><p><strong>Materials and methods: </strong>Patients diagnosed with solid-dominant stage I NSCLC between 2008 and 2015 were included and grouped according to the mode of lymphadenectomy. Disease-free survival (DFS) and overall survival (OS) were compared, and survival analysis was performed among the groups. Cox analysis was used to identify independent prognostic factors. Nomograms for survival prediction on the basis of the lymphadenectomy mode were constructed and internally calibrated. Propensity score matching (PSM) was used to account for potential confounders. Subgroup comparisons between bilateral mediastinal lymphadenectomy (BML), systematic nodal dissection (SND), lobe-specific nodal dissection (L-SND), and selected nodal sampling (SNS) were conducted.</p><p><strong>Results: </strong>In total, 983 patients were included. The 5-year OS rates were 98.2%, 86.9%, 86.4%, and 82.8% (<i>P</i> = .006), and the 5-year DFS rates were 87.1%, 76.4%, 69.5%, and 70.9% (<i>P</i> = .008) in the BML, SND, L-SND, and SNS groups, respectively. Given PSM, patients who underwent BML had longer OS (hazard ratio [HR], 0.358 [95% CI, 0.127 to 1.008]; <i>P</i> = .052) and DFS (HR, 0.563 [95% CI, 0.295 to 1.074]; <i>P</i> = .081) than patients who underwent SND with marginal significance. Compared with L-SND and SNS, BML was associated with significantly improved OS (HR, 0.343 [95% CI, 0.123 to 0.958]; <i>P</i> = .041 and HR, 0.250 [95% CI, 0.088 to 0.709]; <i>P</i> = .009, respectively) and DFS (HR, 0.474 [95% CI, 0.258 to 0.868]; <i>P</i> = .016 and HR, 0.467 [95% CI, 0.232 to 0.938]; <i>P</i> = .032, respectively). Subgroup analyses demonstrated that in male patients and those whose tumors were larger or more advanced, BML was associated with significantly better OS and DFS than other types of lymphadenectomies.</p><p><strong>Conclusion: </strong>BML may be associated with improved survival in patients with solid-dominant stage I NSCLC, and BML is recommended for such patients, especially those with large tumors or more advanced disease.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400219"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Oncology: A Global Perspective on Implementation and Policy Development.","authors":"Denis Horgan, Marcel Tanner, Charu Aggarwal, David Thomas, Surbhi Grover, Lina Basel-Salmon, Rodrigo Dienstmann, Tira Jing Ying Tan, Woong-Yang Park, Hadi Mohamad Abu Rasheed, Lillian L Siu, Brigette Ma, Rocío Ortiz-López, Marc Van den Bulcke, Silvia Castillo Taucher, Andrea Ferris, Naureen Starling, Umberto Malapelle, John Longshore, Hugo Alberto Barrera Saldaña, Vivek Subbiah","doi":"10.1200/GO-24-00416","DOIUrl":"https://doi.org/10.1200/GO-24-00416","url":null,"abstract":"<p><p>Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementation hinges on various factors-scientific complexities not limited to technical, clinical, regulatory, economic, administrative, and health care policy-related challenges. From building infrastructure to the associated costs, including research and development, testing, processing, and trained personnel, a lack of alignment persists. Administrative alignment with regulatory and payor acceptance is crucial. Health care policy must adapt to the ongoing shift from a one-size-fits-all treatment to a personalized approach. Without official endorsement of long-term gains over short-term costs and the health establishment's readiness for innovation, PO prospects, even in prosperous economies, may stagnate. Lower-income countries face exacerbated challenges, intensifying barriers to adoption. Nevertheless, growing awareness and utilization, driven by recognized potential for patients and public health, along with successful examples and advocacy, are progressively influencing policy for a more inclusive and beneficial approach to PO adoption.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400416"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pacific Peoples' Experiences of Cancer and Its Treatment in Aotearoa New Zealand Through Talanoa: A Qualitative Study of Samoan and Tongan Participants.","authors":"Olivia M Perelini, Vili H Nosa, Michelle K Wilson, Nicola J Lawrence, Rob B McNeill, Sheridan Wilson","doi":"10.1200/GO.24.00133","DOIUrl":"https://doi.org/10.1200/GO.24.00133","url":null,"abstract":"<p><strong>Purpose: </strong>In Aotearoa New Zealand, there are inequitable outcomes for Pacific peoples who experience higher rates of preventable cancers and poorer survival compared with other ethnicities. The aim of this study was to explore Pacific peoples lived experience of cancer and its treatment in the Auckland setting.</p><p><strong>Methods: </strong>Data were collected through semistructured interviews (talanoa) with Pacific patients under the Auckland Regional Cancer and Blood Service. A general inductive approach was used to analyze the data. Ethical approval was granted by the Auckland Health Research Ethics Committee (reference number AH24086).</p><p><strong>Results: </strong>Thirteen participants of Samoan and Tongan ethnicity were interviewed. Participants had a range of tumor diagnoses and were receiving curative and noncurative treatments. Five key themes were identified, giving insight into beliefs around cancer, struggles faced by patients, and potential areas of priority. These include (1) cancer means death, (2) holistic and collective approach to support, (3) communication and trust, (4) cost in accessing cancer care and treatment, and (5) Pacific representation.</p><p><strong>Conclusion: </strong>This study sheds light on both positive and negative experiences of Pacific peoples living with cancer in Aotearoa New Zealand. It highlights gaps in the current model of oncology care for this population, which are multilevel and therefore require a multifaceted approach. It calls for priority toward reducing barriers to access of care and creating a more culturally safe pathway.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400133"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Social Media for Medical Oncologists and Medical Oncology Fellows (SMARTY): An Italian Cross-Sectional Study.","authors":"Elena Battaiotto, Carmine Valenza, Mattia Garutti, Luigi Orlando Molendini, Elena Bellio, Dario Trapani, Fabio Puglisi, Gabriella Pravettoni, Luca Buccoliero, Giuseppe Curigliano, Manuelita Mazza","doi":"10.1200/GO-24-00445","DOIUrl":"https://doi.org/10.1200/GO-24-00445","url":null,"abstract":"<p><strong>Purpose: </strong>The use of social media is transforming physician-patient communication, mainly in the field of medical oncology. The pattern of social media use by medical oncologists is poorly studied. Therefore, we developed a survey to understand the preferences, experiences, opinions, and expectations of Italian medical oncologists and oncology fellows regarding the use of social media in cancer medicine to identify the different profiles of social media users.</p><p><strong>Materials and methods: </strong>This multicentric, cross-sectional, observational study included oncologists or oncology fellows from Italy, who were surveyed from July to December 2023 on their use of social media. Data were analyzed through K-means clustering, and the Hartigan-Wong algorithm was applied to identify different profiles of social media users among the participants.</p><p><strong>Results: </strong>Of the 245 participants who accepted the invitation, 116 completed the entire survey and were included in the cluster analysis. Three profiles of social media users were identified through clustering: the highly social, the social skeptic, and the moderately social, accounting for 31%, 31%, and 38% of the participants, respectively. In general, older age (<i>P</i> = .0001), being a specialized oncologist (<i>P</i> = .003), and a higher mean time spent on social media (<i>P</i> = .0001) were associated with a greater consideration of the professional use of social media.</p><p><strong>Conclusion: </strong>The use of social media among medical oncologists and oncology fellows represents a spectrum ranging from the social skeptic user to the highly social. Age, professional status (specialist or fellow), and frequency on social media use were associated with different patterns, opinions, and behaviors related to social media use.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400445"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Cancers in Kerala, India: A Review of Population-Based Registry Data.","authors":"Jeffrey Mathew Boby, Deepak Varughese, Jame Mathew Benny, Mathew Thomas, Aju Mathew","doi":"10.1200/GO-24-00395","DOIUrl":"10.1200/GO-24-00395","url":null,"abstract":"<p><strong>Purpose: </strong>Kerala in India leads the nation in both Human Development Index and Sustainable Development Index. The state is a harbinger for the rest of the country in matters of health. Documentation of cancer trends and quantifying the cancer burden is crucial for planning oncology services in the country. In this study, we aim to perform a time series analysis using data from the National Cancer Registry.</p><p><strong>Methods: </strong>Data for crude incidence, age-adjusted incidence, and disease-specific incidence were extracted from published reports of the Population-Based Cancer registries at Kollam and Thiruvananthapuram. Data collected between 2006 and 2008 were analyzed and published in 2010. Data collected between 2012 and 2016 were published in 2020. Descriptive statistics was used for analysis.</p><p><strong>Results: </strong>Age-adjusted incidence rates increased from 121.7 per 100,000 men to 137.8 in Thiruvananthapuram from 2006-2008 to 2012-2016 period. Among women, in Thiruvananthapuram, the age-adjusted rates increased from 108.3 to 127.3. In Kollam, the age-adjusted incidence rate increased from 113.3 to 127.1 among men and 89.7 to 107.1 among women. Lung and breast cancers remain the most common cancers among men and women.</p><p><strong>Conclusion: </strong>There has been an increase in both crude and age-adjusted incidence rates in Kerala. However, these changes are in line with global trends in cancer incidence. Lifestyle changes and reduced tobacco and alcohol use will help decrease the incidence of cancer in Kerala.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400395"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observational Study of Best Supportive Care With or Without Oral Capecitabine in Patients With Metastatic Gallbladder Carcinoma at a Tertiary Center in India.","authors":"Abhinav Srivastava, Shagun Misra, Neeraj Rastogi, Vishwas Kapoor, Shaleen Kumar","doi":"10.1200/GO-24-00341","DOIUrl":"10.1200/GO-24-00341","url":null,"abstract":"<p><strong>Purpose: </strong>To compare overall survival (OS), toxicity, and quality of life (QOL) in patients with metastatic gallbladder cancer receiving oral capecitabine (X) with best supportive care (BSC) and BSC alone.</p><p><strong>Materials and methods: </strong>Patients with metastatic gallbladder cancer and Karnofsky Performance Status (KPS) ≥70 were accrued and assigned to either arm A or B. Assignment to these two arms was based on physician/patient discretion. Arm A received oral capecitabine 825 mg/m² twice a day d1-14, repeated every 3 weeks for six cycles with BSC, and arm B received BSC alone. The Kaplan-Meier method computed OS and comparison was using a log-rank test. QOL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 administered at baseline, 3 months, and 6 months. The linear mixed-effects model was used for the longitudinal analysis of QOL.</p><p><strong>Results: </strong>Between December 2020 and April 2022, 64 patients diagnosed with metastatic gallbladder carcinoma and KPS ≥70 were accrued in the study, and 32 patients were assigned to each arm. In arm A versus B, the median age was 52 versus 55 (<i>P</i> = .21); the median KPS was 80 versus 70 (<i>P</i> = .008). The median OS in arm A versus B was 3.4 versus 2 months (<i>P</i> = .001). Grade 1-2 vomiting and diarrhea were seen in 50% versus 78% (<i>P</i> = .041) and 59% versus 9.3% (<i>P</i> = .01) patients in arm A versus B, respectively. Grade 1-2 hand-foot syndrome was seen in 12 (37.5%) patients in arm A. Dynamic changes showed an improvement in pain in the linear mixed model with a significant difference between the arms (<i>P</i> = .011); arm A experienced a significant improvement in pain over time (arm × time <i>P</i> = .020). Global QOL improved over time (<i>P</i> = .038) with parallel improvement between arms (arm × time <i>P</i> = .490).</p><p><strong>Conclusion: </strong>Compared with BSC alone, patients who receive X + BSC experience an OS improvement of 1.4 months and better pain control without grade 3 toxicities or negative impact on QOL.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400341"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study.","authors":"Abigia Ashenafi, Soliyana Demelash, Efrata Melaku, Haymanot Abe, Meron Yitna, Fisseha Tekle, Jiksa Dabessa, Biniam Araya, Yared Nigussie, Wondmagegn Demsiss, Ashenafi Zelalem, Song Jung Kim, Nebiyu Dereje","doi":"10.1200/GO-24-00468","DOIUrl":"https://doi.org/10.1200/GO-24-00468","url":null,"abstract":"<p><strong>Purpose: </strong>To analyze survival and its predictors among patients with hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in Ethiopia.</p><p><strong>Materials and methods: </strong>We conducted a retrospective cohort study among patients who received TACE for HCC at MCM Hospital from December 1, 2016, to December 31, 2022. Data were extracted from patients' medical records, and vital status was ascertained from the patients' charts or by phone call to the next of kin. We used Kaplan-Meier estimator to determine survival functions and log-rank test to compare the survival functions in different groups. Predictors of survival were identified using a multivariable Cox proportional hazards regression model as expressed by adjusted hazard ratio (aHR).</p><p><strong>Results: </strong>Of the total 257 patients included in the study, 68.9% were male, with a mean age of 56.5 (±14.06) years, and 86% were diagnosed at the advanced stage of the cancer (Barcelona Clinic Liver Cancer-C). The median overall survival was 12.7 months (95% CI, 10.57 to 14.85), and the overall survival rate at 1 year, 2 years, 3 years, 4 years, 5 years, and 6 years was found to be 58.0% (95% CI, 51.8% to 63.8%), 24.1% (95% CI, 19.1% to 29.6%), 8.2% (95% CI, 5.1% to 11.7%), 7.0% (95% CI, 3.9% to 10.1%), 1.6% (95% CI, 0.4% to 3.1%), and 1.2% (95% CI, 0.1% to 2.7%), respectively. The probability of death was significantly increased by alpha-fetoprotein level <400 ng/mL (aHR, 5.72 [95% CI, 1.52 to 21.51]), albumin level (aHR, 5.03 [95% CI, 1.41 to 18.01]), and bilobar distribution (aHR, 5.67 [95% CI, 1.40 to 23.04]).</p><p><strong>Conclusion: </strong>The findings of the study underscore the need for the expansion of preventive measures and treatment facilities to address the overwhelming burden of HCC in Ethiopia.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400468"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}